The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...

New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don't. Researchers from the Garvan Institute of ...

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell ...

Prognostic factors and long-term survivors in EGFR-mutated lung cancer: A multi-institutional retrospective analysis. Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR ...

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for ...

BriaCell (BCTX) Therapeutics reports preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, ...

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related ...

FDA accepts BLA for INO-3107, a DNA immunotherapy for HPV-6 and HPV-11-associated recurrent respiratory papillomatosis.

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 receptors to enhance T cell-mediated cancer cell attack.